Balovaptan + Placebo
Phase 2Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Ischemic Stroke
Conditions
Acute Ischemic Stroke
Trial Timeline
Jun 22, 2022 → Nov 17, 2022
NCT ID
NCT05399550About Balovaptan + Placebo
Balovaptan + Placebo is a phase 2 stage product being developed by Roche for Acute Ischemic Stroke. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05399550. Target conditions include Acute Ischemic Stroke.
What happened to similar drugs?
20 of 20 similar drugs in Acute Ischemic Stroke were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05401565 | Phase 2 | Completed |
| NCT05399550 | Phase 2 | Withdrawn |
| NCT03504917 | Phase 3 | Terminated |
Competing Products
20 competing products in Acute Ischemic Stroke